SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,415,971 | +1294.3% | 165,985 | +2088.6% | 0.01% | +800.0% |
| Q2 2022 | $245,000 | -70.8% | 7,584 | -70.1% | 0.00% | -50.0% |
| Q1 2022 | $840,000 | -50.0% | 25,364 | -35.8% | 0.00% | -33.3% |
| Q4 2021 | $1,681,000 | +11.5% | 39,519 | +16.1% | 0.00% | 0.0% |
| Q3 2021 | $1,508,000 | -4.9% | 34,046 | +22.0% | 0.00% | 0.0% |
| Q2 2021 | $1,585,000 | -12.4% | 27,905 | +15.4% | 0.00% | -25.0% |
| Q1 2021 | $1,809,000 | -87.0% | 24,171 | -85.0% | 0.00% | -85.7% |
| Q4 2020 | $13,917,000 | +3.0% | 160,867 | -27.2% | 0.03% | -12.5% |
| Q3 2020 | $13,510,000 | +49.3% | 221,042 | +1.6% | 0.03% | +45.5% |
| Q2 2020 | $9,046,000 | +313.1% | 217,555 | +185.3% | 0.02% | +266.7% |
| Q1 2020 | $2,190,000 | +147.7% | 76,242 | +1478.5% | 0.01% | +200.0% |
| Q2 2019 | $884,000 | +4.6% | 4,830 | -10.5% | 0.00% | 0.0% |
| Q2 2018 | $845,000 | -84.4% | 5,399 | -84.0% | 0.00% | -87.5% |
| Q1 2018 | $5,423,000 | +218.1% | 33,670 | +225.2% | 0.02% | +220.0% |
| Q4 2017 | $1,705,000 | -96.4% | 10,354 | -98.6% | 0.01% | -96.3% |
| Q3 2017 | $46,884,000 | -33.8% | 752,557 | -15.3% | 0.13% | -34.3% |
| Q2 2017 | $70,784,000 | +3.7% | 888,791 | -7.5% | 0.20% | +4.6% |
| Q1 2017 | $68,277,000 | +39.3% | 960,700 | +0.1% | 0.20% | +32.7% |
| Q4 2016 | $49,007,000 | -13.1% | 959,800 | -21.6% | 0.15% | -9.3% |
| Q3 2016 | $56,374,000 | +534.3% | 1,224,200 | +315.0% | 0.16% | +523.1% |
| Q2 2016 | $8,888,000 | +13.2% | 295,000 | +20.4% | 0.03% | +8.3% |
| Q1 2016 | $7,855,000 | -34.3% | 245,000 | +19.5% | 0.02% | -36.8% |
| Q4 2015 | $11,952,000 | +38.0% | 205,000 | +0.1% | 0.04% | +35.7% |
| Q3 2015 | $8,663,000 | -41.9% | 204,700 | +0.2% | 0.03% | -37.8% |
| Q2 2015 | $14,907,000 | +45.3% | 204,200 | 0.0% | 0.04% | +45.2% |
| Q1 2015 | $10,257,000 | +37.2% | 204,200 | 0.0% | 0.03% | +34.8% |
| Q4 2014 | $7,474,000 | +16.2% | 204,200 | 0.0% | 0.02% | +9.5% |
| Q3 2014 | $6,432,000 | – | 204,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |